Ligands for opioid and sigma-receptors improve cardiac electrical stability in rat models of post-infarction cardiosclerosis and stress.
The effects of the extremely selective mu-opioid receptor agonist, [D-Arg2,Lys4]-dermorphin-(1-4)-amide (DALDA), the mu-opioid receptor agonist morphine, the mu/delta agonist D-Ala2, Leu5, Arg6-enkephalin (dalargin), the kappa-opioid receptor agonist spiradoline, and the sigma1-receptor antagonist DuP 734 on ventricular fibrillation threshold (VFT) was investigated in an experimental post-infarction cardiosclerosis model and an immobilization stress-induced model in rats. Both models produced a significant decrease in VFT. The postinfarction cardiosclerosis-induced decrease in VFT was significantly reversed by intravenous administration of dalargin (0.1 mg/kg), DALDA (0.1 mg/kg), or morphine HCl (1.5 mg/kg). Pretreatment with naloxone (0.2 mg/kg) completely eliminated the increase in cardiac electrical stability produced by DALDA. Both spiradoline (8 mg/kg, i.p.) and DuP 734 (1 mg/kg, i.p.) produced a significant increase in VFT in rats with post-infarction cardiosclerosis. This effect of spiradoline was blocked by nor-binaltorphimine. The immobilization stress-induced decrease in VFT was significantly reversed by administration of either DALDA, spiradoline or DuP 734. In conclusion, activation of either mu- or kappa1-opioid receptors or blockade of sigma1-receptors reversed the decrease in VFT in both cardiac compromised models. Since DALDA and dalargin essentially do not cross blood brain barriers, their effects on VFT may be mediated through peripheral mu-opioid receptors.
Lishmanov YuB
Department of Experimental Cardiology, Institute of Cardiology, Tomsk, Russia.
Maslov
L N
LN
Naryzhnaya
N V
NV
Tam
S W
SW
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D004195:Disease Models, Animal; D004399:Dynorphins / Q000494:pharmacology; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives / Q000494:pharmacology; D006321:Heart / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D007103:Immobilization; D008024:Ligands; D009020:Morphine / Q000494:pharmacology; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology*; D009206:Myocardium / Q000473:pathology*; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists; D009842:Oligopeptides / Q000037:antagonists & inhibitors / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011759:Pyrrolidines / Q000037:antagonists & inhibitors / Q000494:pharmacology; D051381:Rats; D011957:Receptors, Opioid / Q000819:agonists / Q000502:physiology*; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors / Q000502:physiology*; D013312:Stress, Physiological / Q000503:physiopathology*; D014693:Ventricular Fibrillation / Q000188:drug therapy; D001615:beta-Endorphin / Q000494:pharmacology
D000889:Anti-Arrhythmia Agents; D008024:Ligands; D009292:Narcotic Antagonists; D009842:Oligopeptides; D010880:Piperidines; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; C063076:tyrosyl-arginyl-phenylalanyl-lysinamide; D009270:Naloxone; C051844:norbinaltorphimine; D009271:Naltrexone; D001615:beta-Endorphin; D016308:Enkephalin, Leucine-2-Alanine; D004399:Dynorphins; D009020:Morphine; C078773:DuP 734; C051272:spiradoline; C040996:enkephalin-Leu, Ala(2)-Arg(6)-